BioPharmSignal logoBioPharmSignal

Biotech News

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems (RPID)Rapid Micro BiosystemsEarnings

Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed globally; placed four Growth Direct systems and completed nine validations in the second quarter

Related news

RPIDRapid Micro Biosystems2026-07-23 21:15 EST

Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026

RPIDRapid Micro Biosystems2026-05-13 20:26 EST

Rapid Micro Biosystems Reports First Quarter 2026 Financial Results

View all latest news

Rapid Micro Biosystems

Automated Microbial Quality Control Rapid Micro Biosystems provides automation systems used to test biologics, vaccines, cell and gene therapies, sterile injectables, and other healthcare products for microbial contamination. Growth Direct Platform The Growth Direct system replaces manual microbial quality-control workflows with...

Recent company news

RPIDRapid Micro Biosystems2026-08-07 11:00 EST

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

RPIDRapid Micro Biosystems2026-08-04 20:30 EST

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RPIDRapid Micro Biosystems2026-07-23 21:15 EST

Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026

RPIDRapid Micro Biosystems2026-06-10 20:30 EST

Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RPIDRapid Micro Biosystems2026-05-19 01:55 EST

Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering

Stock data

Close
1.68 USD
Market cap
97.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States